Bio News
Efficacy demonstrated in phase 3 trial for nonobstructive hypertrophic cardiomyopathy (HCM) Peak oxygen uptake increased by 0.64 mL/kg/min; annual sales expected to reach $7 billion
Cytokinetics’ heart disease treatment Myqorzo succeeded in a phase 3 trial for nonobstructive hypertrophic cardiomyopathy (HCM), sending the company’s shares up 17%. In the trial, Myqorzo increased peak oxygen uptake by 0.64 mL/kg/min and showed a significant improvement compared with placebo. The company plans to discuss approval with regulatory authorities, and the market is estimated to be worth more than $5 billion annually (approximately 7 trillion won).
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
